Trilipix

The FDA changed the label for Trilipix fenofibric acid, Abbott and is notifying healthcare professionals that the drug "may not lower a patient's risk of having a heart attack or stroke."

Forbes.com: News Larry Husten 2011

The negative outcome could hurt sales of TriCor and a newer, follow-up drug from Abbott called Trilipix, which generated combined sales of $1.3 billion for Abbott in 2009.

Abbott's TriCor Underperforms in Diabetes Test Peter Loftus 2010

The negative outcome could hurt sales of TriCor and a newer, follow-up drug from Abbott called Trilipix, which generated combined sales of $1.3 billion for Abbott in 2009.

Abbott's TriCor Underperforms in Diabetes Test Peter Loftus 2010

The negative outcome could hurt sales of TriCor and a newer, follow-up drug from Abbott called Trilipix, which generated combined sales of $1.3 billion for Abbott in 2009.

Abbott's TriCor Underperforms in Diabetes Test Peter Loftus 2010

Wells Fargo analyst Larry Biegelsen said the most likely outcome of Thursday's meeting will be the addition of new study data to the Trilipix label.

FDA panel to weigh revoking key use of Trilipix 2011

But a 5,000-patient government study released in March showed that diabetic patients taking Trilipix plus a statin had just as many heart attacks as patients taking a statin alone.

FDA panel to weigh revoking key use of Trilipix 2011

Humira sales rose 13% to $1.68 billion, while combined sales of cholesterol drugs Trilipix and TriCor rose 22% to $404 million.

Abbott Profit Falls 40% on Acquisition, Recall Costs Peter Loftus 2010

North Chicago-based Abbott Laboratories reported combined sales of $1.6 billion last year for Trilipix and TriCor, an older drug that contains the same active ingredient.

FDA panel to weigh revoking key use of Trilipix 2011

Pressuring sales growth were a 1.2% decline in sales of coronary stents; and declines in sales of cholesterol drugs TriCor, Trilipix and Niaspan.

Abbott's Earnings Rise Peter Loftus 2012

The group will also discuss data from the study that showed a higher rate of heart attacks among women who took Trilipix in combination with a statin.

FDA panel to weigh revoking key use of Trilipix 2011